Peptide-Based Vaccines Against Viruses: Current Platforms and Future Directions
Peptide-based vaccines offer precise antigen targeting, safety, and scalability for viral pathogens, with advanced delivery systems and computational design accelerating development for emerging infectious diseases.
Quick Facts
What This Study Found
Peptide vaccines: precise antigen targeting, safety, scalability for viral pathogens. Advanced delivery (NPs, liposomes, VLPs) and computational design accelerating development. Challenges: immunogenicity, HLA diversity, adjuvant needs.
Key Numbers
How They Did This
Narrative review of peptide vaccine platforms for viral pathogens, covering antigen design, delivery systems, computational methods, and clinical development.
Why This Research Matters
Pandemic preparedness requires rapid vaccine platforms. Peptide vaccines can be designed computationally and manufactured quickly for emerging viruses.
The Bigger Picture
Peptide vaccines represent the fastest-to-manufacture platform for pandemic response, with computational design enabling near-real-time antigen selection for new viral threats.
What This Study Doesn't Tell Us
Most peptide vaccines are still in clinical development. Immunogenicity remains a fundamental challenge requiring effective delivery/adjuvant solutions.
Questions This Raises
- ?Will peptide vaccines achieve efficacy comparable to mRNA vaccines?
- ?Can computational design solve the HLA diversity challenge?
- ?Would universal influenza peptide vaccines be feasible?
Trust & Context
- Key Stat:
- Fast and precise Peptide vaccines can be computationally designed and rapidly manufactured for emerging viral threats — precision immunization for pandemic preparedness
- Evidence Grade:
- Comprehensive review of the field with clinical development data.
- Study Age:
- Published in 2025.
- Original Title:
- Advancing peptide-based vaccines against viral pathogens: a narrative review.
- Published In:
- Therapeutic advances in infectious disease, 13, 20499361251411188 (2026)
- Authors:
- Jahantigh, Hamid Reza, Rezanavaz Gheshlagh, Solaleh, Mafakher, Ladan(2), Ahmadi, Nahid, Shahbazi, Behzad, Ahmadi, Khadijeh
- Database ID:
- RPEP-15363
Evidence Hierarchy
Frequently Asked Questions
What is a peptide vaccine?
Instead of using whole viruses or mRNA, peptide vaccines use specific small protein pieces that teach the immune system exactly what to attack. They are safe, precise, and fast to manufacture.
Why aren't peptide vaccines more common?
Peptides alone don't stimulate strong immune responses. Researchers are solving this with nanoparticle delivery, new adjuvants, and computational design — making peptide vaccines increasingly competitive.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15363APA
Jahantigh, Hamid Reza; Rezanavaz Gheshlagh, Solaleh; Mafakher, Ladan; Ahmadi, Nahid; Shahbazi, Behzad; Ahmadi, Khadijeh. (2026). Advancing peptide-based vaccines against viral pathogens: a narrative review.. Therapeutic advances in infectious disease, 13, 20499361251411188. https://doi.org/10.1177/20499361251411188
MLA
Jahantigh, Hamid Reza, et al. "Advancing peptide-based vaccines against viral pathogens: a narrative review.." Therapeutic advances in infectious disease, 2026. https://doi.org/10.1177/20499361251411188
RethinkPeptides
RethinkPeptides Research Database. "Advancing peptide-based vaccines against viral pathogens: a ..." RPEP-15363. Retrieved from https://rethinkpeptides.com/research/jahantigh-2026-advancing-peptidebased-vaccines-against
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.